Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · IEX Real-Time Price · USD
35.60
+0.73 (2.09%)
At close: Jul 26, 2024, 4:00 PM
35.89
+0.29 (0.81%)
After-hours: Jul 26, 2024, 6:55 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $146.81M in the quarter ending March 31, 2024, with 38.95% growth. This brings the company's revenue in the last twelve months to $523.53M, up 26.51% year-over-year. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$523.53M
Revenue Growth
+26.51%
P/S Ratio
7.08
Revenue / Employee
$1,487,298
Employees
352
Market Cap
3.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.56B |
| Surgery Partners | 2.79B |
| Prestige Consumer Healthcare | 1.13B |
| Sotera Health Company | 1.08B |
| Neogen | 929.24M |
| Alvotech | 114.39M |
| Merus | 38.34M |
| Arrowhead Pharmaceuticals | 35.47M |
CORT News
- 4 days ago - Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 9 days ago - These small-cap stocks score highest when screened for quality - Market Watch
- 4 weeks ago - Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions - GlobeNewsWire
- 7 weeks ago - Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) - GlobeNewsWire
- 2 months ago - Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 3 months ago - Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 4 months ago - Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome - GlobeNewsWire